Somnibene GmbH   Report issue

For profit Phase 3
Founded: Schwerin Germany (2004)
Status: No NME R&D (2004)

Organization Overview

First Clinical Trial
2006
NCT00367822
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

lisuride (Dopergin) (1 trial)

ropinirole (Requip) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Psychomotor Agitation (Phase 3)

Restless Legs Syndrome (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2